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Abstract
Background: The appropriate use of anti-malarial drugs determines therapeutic efficacy and the emergence and
spread of drug-resistant malaria. Strategies for improving drug compliance require accurate information about
current practices at the consumer level. This is to ascertain that the currently applied new combination therapy to
malaria treatment will achieve sustained cure rates and protection against parasite resistance. Therefore, this cross-
sectional study was designed to determine knowledge and behaviour of the consumers in households (n = 397) in
peri-urban location in a malaria holoendemic region of western Kenya.
Methods: The knowledge and behaviour associated with anti-malarial use were evaluated. Using clusters, a
questionnaire was administered to a particular household member who had the most recent malaria episode
(within <2 weeks) and used an anti-malarial for cure. Mothers/caretakers provided information for children aged
<13 years.
Results: Consumers’ knowledge on dosage and duration/frequency demonstrated that only 29.4% used the
correct artemisinin-based combination therapy (ACT) dosage. Most respondents who used quinine identified the
correct duration of use (96.4%) since its administration was entirely at health facilities. To assess behaviours during
use of anti-malarial drugs, respondents were stratified into those who took drugs with prescription (39.4%) and
without prescription (61.6%). For those without prescription, the reasons given were; procedure of acquisition less
costly (39.0%), took same drug for similar symptoms (23.0%), not satisfied with health services (15.5%), neighbour/
friend/relative previously taken the same drug (12.5%) and health institution was far from their location (10%).
Conclusion: Majority of consumers in the study area were knowledgeable on the symptoms of malaria. In
addition, majority acquired ineffective anti-malarial drugs for treatment and reported sub-optimal treatment
regimens with the currently recommended drugs. Furthermore, behaviours which constrain the successful up-
scaling of ACT were common, creating a challenge in the desire to turn efficacy to effectiveness of the
combination therapy programme. It will be important to direct and focus interventions in creating awareness on
the importance of using recommended drugs to lessen the use of less efficacious anti-malarials. In addition, the
consumers need to be educated on the importance of drug adherence in such areas to reduce the emergence
and spread of drug-resistant malaria.
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The burden of malaria persists in many parts of Africa
despite the availability of many interventions that are
focused on preventive and therapeutic strategies [1]. For
instance, the Roll-Back Malaria (RBM) initiative is work-
ing to improve prevention efforts in affected countries,
through insecticide-treated nets (ITNs), indoor residual
spraying (IRS) of pesticides, and intermittent preventive
treatment (IPT) for pregnant women [1]. Other inter-
ventions focus on effective anti-malarial regimens like
artemisinin-based combination therapy (ACT) and
improving home management of the disease [2]. The
development of resistance by malaria parasites to more
affordable anti-malarial drugs such as chloroquine and
sulphadoxine-pyrimethamine has called for the use of
ACT as the most effective treatment option in sub-
Saharan Africa [3]. Since most individuals in sub-
Saharan Africa opt to treat malaria without visiting a
medical facility, appropriate use of anti-malarial drugs is
vital to effective treatment of the disease [2]. The cor-
rect use of anti-malarial drugs is not only key, not only
to therapeutic success, but is also paramount in deter-
ring the spread of drug-resistant malaria [4].
The pattern of anti-malarial drug use in endemic areas
of Africa is quite different from the use of other drugs
due to the high intensity of malaria transmission in
these regions. In areas of intense malaria transmission,
anti-malarial drugs are given repeatedly to treat frequent
fevers (even in the absence of malaria) [5]. The practice
of self-medication is also increasingly becoming a major
health concern. Research findings show that many ill-
nesses including malaria, are treated without consulta-
tions with health professionals [6]. In areas where
malaria transmission is endemic, about 50-80% of peo-
ple first visit private drug outlets for malaria treatment
and use these anti-malarial drugs even without prescrip-
tion [7]. Most studies in Kenya have examined retail tra-
ders and health care providers of anti-malarial drugs, in
order to address the anti-malarial dispensing level
[8-10]. However, consumers also play a critical role in
determining how these drugs are used. Understanding
the knowledge and behaviour of consumers and how
they actually use antimalarial will aid in devising strate-
gies to increase the correct use of these drugs.
T h ec u r r e n ts t u d ys i t e ,ap e r i - u r b a nl o c a t i o nw i t h i n
Kisumu, is situated in a Plasmodium falciparum holoen-
demic transmission area of western Kenya. Malaria in this
region accounts for about 40% of out-patient visits, and
about 40% of hospital in-patient admissions [11]. Malaria
transmission occurs all year round, peaking in the rainy
season months of April and May [12]. The National
Malaria Control Programme in Kenya recommends ACT-
artemether/lumefantrine as the first-line drug for uncom-
plicated malaria and for chemoprophylaxis in pregnancy.
Quinine is the second line anti-malarial, and is the recom-
mended treatment for severe and complicated malaria.
Studies have previously observed that anti-malarial
drugs are bought from commercial pharmacists, street
vendors, retail shops (e.g. grocery) or from licensed and
unlicensed drug sellers [13,14]. Additional studies also
observed that most patients reporting at the health facil-
ities would have at least gone through home-based
treatment or local drug shops initially [13,14]. Hence,
there is concern that household and communities’ pat-
terns of use of anti-malarial drugs are often inadequate
and inappropriate depending on the knowledge and
behaviour adopted for use of other medicines, not only
for malaria [13]. It is upon this background that the cur-
rent study on behaviours and knowledge determining
the patterns of anti-malarial drug use among the resi-
dents of a peri-urban region of Kisumu in western
Kenya, was carried out.
Methods
Study setting
The current study was carried out in Manyatta-B sub-
location in Winam division of Kisumu as previously
d e s c r i b e di no u rr e c e n tp u b l i c a t i o n[ 1 4 ] .I nb r i e f ,t h e
area consists of three villages, Lower Kanyakwar, Upper
Kanyakwar and Kuoyo, which are further divided into
nine smaller units depending on the sub-clan bound-
aries. Within the sub-clan boundaries are informal
dwellings. According to the last population census, the
total number of inhabitants in this sub-location is
21,027 in 6,035 households [15]. The total area is
3.3 km
2 with a density of 6, 372 people/km
2 [15]. Hous-
ings consist, mostly, of rented rooms within an area of
10-20 m
2 for 4-8 persons in a household [14]. These
individuals live in a congested and miserable conditions,
with considerable lack of the basic necessities of life,
such as clean piped-water and proper housing condi-
tions [16]. There is poor drainage and lots of stagnant
water, which form good breeding grounds all year round
for malaria vectors [17].
Study participants
In order to establish the knowledge and behaviour
determining use of anti-malarial drugs in the study
population at a point in time, residents living within
households (n = 397) in the above described peri-urban
region of Kisumu in western Kenya, were recruited.
This was a descriptive cross-sectional survey in which
sampling was carried out using cluster method as pre-
viously described [13,18]. A total of 6,035 households in
nine clusters were sampled in order to achieve the
required sample size as previously described [14]. Data
were collected through interviews, using structured
questions in selected households in which diagnosed or
Watsierah et al. Malaria Journal 2011, 10:99
http://www.malariajournal.com/content/10/1/99
Page 2 of 7self-reported episodes of malaria occurred within the
last two weeks prior to the interview dates.
Included in the study were individuals living in the
above-described households and who had experienced
malaria and used anti-malarial or other drugs perceived
by them as anti-malarial, due to self/presumptive or
laboratory diagnosis within the previous two weeks. In
the absence of laboratory diagnosis, malaria according
to residents in the study area was defined by either the
presence or mixed symptoms of headache, high tem-
perature, shivering, diarrhoea, vomiting and pain in the
joints. However, if more than one individual in a house-
hold had experienced malaria-related symptoms and had
used anti-malarial or other drugs viewed or perceived by
them as anti-malarial withint h ed e s c r i b e dp e r i o d( i . e .
two weeks), then focus was on the most current episode,
while the rest were excluded. This strategy was adopted
so as to capture the most recent knowledge and beha-
viour associated with anti-malarial drug use and to
minimize errors associated with recall. If no one had
experienced malaria episodes within the previous two
weeks, the interviewer moved to the next household in
the cluster. Correct drug use was assessed by question-
naires through identification of the drug used and
whether or not the respondents used it as per the pre-
scription. The study was approved by the ethical and
scientific review committees at the Kenya Medical
Research Institute and the Great Lakes University of
Kisumu Ethical Review Board (GERB), Kenya.
Sampling design
As previously defined in our publication [14], the study
employed cluster sampling method in selecting the
households in the study area. A total of nine clan
regions were chosen as clusters. The study units com-
prised households within the cluster that had its mem-
ber experiencing malaria in the last two weeks. The
probability of selection of the primary sampling units
for each cluster was proportional to the estimated sam-
ple size. From each cluster, households were then
selected on continuous basis until the total number (n =
397) required was achieved.
Research procedure
The quantitative data, which were collected from 397
households, were obtained through interviews using
structured questions. The tool for data collection was a
pre-prepared questionnaire, which was administered to
the particular household member, who had previous
malaria episode and used anti-malarial or drug perceived
to be an anti-malarial. However, in case of children
below the age of 13 years, mothers or caretakers pro-
vided the information. Using clusters, households which
had experienced malaria episodes were established first
through identification interview, which involved all the
households starting with exactly the first household vis-
ited in the cluster. The interview was then repeated in
all the households identified until the required number
was achieved. As stated above, particular emphasis was
on the most recent episode of self/presumptive or
laboratory diagnosed malaria in the household.
Research/field assistants (n = 5) who were involved in
data collection, used drug charts containing samples of
commonly used anti-malarial drugs to aid in recall and
to validate reports. In addition, remaining packages or
tablets were reviewed where possible.
Prior to the actual study, the field assistants who were
themselves residents of the study sub-location and with
a minimum of form four level of education, were inter-
viewed and recruited as enumerators. They were
required to be fluent in English, Swahili and Dho-Luo
languages. Training of the research assistants on survey
interviewing techniques was carried out for one day fol-
lowed by a second day of pre-testing of survey tools and
methodologies in a neighbouring community with the
same characteristics. Based on the experiences and
results of the pre-test, further re-training and refining of
techniques of interviewing and modification of research
tools were performed.
Statistical analyses
Statistical analyses were performed using SPSS (Version
15.0). Logistic regression analysis between the indepen-
dent and dependent variables was used to identify vari-
ables associated with pattern of use of anti-malarial
drugs. The variables include di nt h el o g i s t i cr e g r e s s i o n
model comprised knowledge of (symptoms for use,
dosage, duration, anti-malarials availability apart from
what was taken). The variables that were significantly
associated with pattern of use (correct drugs taken, cor-
rect duration, and correct dosage) were further analyzed
using Chi-square tests. Proportions on knowledge, drug-
taking behaviour and correctness of patterns of use were
determined. A P≤0.05 was considered statistically
significant.
Results
The use of anti-malarial drugs
Overall, 32.5% of households in Manyatta-B acquired
and used ACT as first choice of anti-malarial drug while
37.0% acquired and used SP. The use of ACT was
reported mostly by users who acquired anti-malarials
from government health institutions (42.1%) and from
pharmacies/chemists (32.0%). Eighty three percent (83%)
of the SP users cited low price of the drug and/or its
availability at the source as the basis for the use of the
drug. In general, the proportions of those who acquired
other anti-malarials other than ACT and SP were
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2.0%, and antipyretic = 11.1%) with 3.0% using cough
syrup (perceived to be an anti-malarial) (Figure 1).
Knowledge level and pattern of anti-malarial drugs use in
Manyatta-B
In order to assess the knowledge level on drug used, the pat-
tern of anti-malarial use (symptoms for use, dosage, dura-
tion/frequency and available anti-malarials) was evaluated.
Table 1 presents data on the pattern of anti-malarial drugs
used in Manyatta-B. Results revealed that most of the
respondents who had taken anti-malarial drugs reported
high temperatures (48.4%), headache (39.4%), vomiting
(7.6%) and shivering (4.0%) as symptoms for anti-malarial
drug use, while the rest (0.6%) reported other symptoms
(coughs, pregnancy-related and acute respiratory infections).
Consumers’ knowledge on the dosage and duration/fre-
quency was further assessed on respondents who
reported using the anti-malarial drugs. Most of SP consu-
mers used the correct dosage (85.0%) and within the cor-
rect duration (82.0%) (Table 1). Only 29.4% of the
consumers who reported having used ACT could identify
the correct daily adult dose of 8 tablets (ACT-arte-
mether/lumefantrine, commonly available in 20/120-mg
tablet size) (Table 1). All other ACT users (70.6%)
reported taking fewer than eight tablets a day. Similarly,
of those who responded to the question of duration of
ACT therapy, the majority (67.0%) responded incorrectly,
mostly identifying shorter treatment duration (less than 3
days) (Table 1). Most respondents who used quinine
could identify the correct duration of use (96.4%) since
its administration was entirely done in health facilities
(Table 1). All of the consumers that used amodiaquine
either could not remember or declined to respond to
questions on dosage and duration (Table 1).
Behaviours in anti-malarial drug use
In this study, behaviour was defined as habitual prac-
tices, actions or deeds an individual or households carry
out with an anti-malarial drug. In order to assess beha-
viours during the use of anti-malarial drugs, respondents
were first stratified into those who took drugs with pre-
scription (39.4%) and without prescription (61.6%). For
those who had no prescription, the reasons given were
as follows; 39.0% said procedure of acquisition was less
costly, 23.0% took same drug for similar symptoms,
15.5% were not satisfied with health services/institutions,
12.5% had neighbour/friend/relative previously taking
the same drug and 10% said health institution was far
from their location.
In addition, there were notable differences between
proportions of those who bought full dosage of drugs
(39.1%) versus those who did not (60.9%). For those
who did not buy full drug dosage, they gave the follow-
ing reasons; 67.3% could not afford, 16.8% got better
after taking few tablets, 14.4% said symptoms were mild
and so there was no need of buying full dosage, while
1.4% gave other reasons not listed in the questionnaire.
When asked about how drugs were taken, 63.9%
reported to have taken drugs according to advice given
at the source while 36.1% reportedly did not take drugs
according to advice given. Reasons for not taking drugs
according to advice were mainly; 41.4% kept drugs for
future episodes of the same illness, 33.0% got better
hence discontinued, and 16.2% shared the dosage with
another person while the rest gave other actions not
listed on the questionnaire.
When asked about the drug used, 34.6% of the
respondents reported the drugs used for treatment was
always available at source, 20.9% said the drug of has a
faster action, 18.8% reported that they have been using
the same drug for the same ailment/symptoms, 12.0%
reported that the drug used had no side effects, 9.4%
reported that the drug had fewer number of dosages per
treatment course and 4.3% included other reasons. In
terms of day of first use of drugs after the symptoms
started, 34.3% took drugs the same day (within 12 hours
of illness), 38.5% took drugs the next day (within 24
hours of illness), 17.6% took drugs two days after
Figure 1 Anti-malarial drugs used in households in Manyatta-B.
ACT-Artemether combined therapy, SP-Sulphadoxine-
pyrimethamine, AQ-Amodiaquine. SP was the most commonly used
anti-malarial drug, followed with ACT.
Table 1 Anti-malarial drugs taken and the doses and
duration with which they were used in Manyatta B.
Drugs taken Duration of use Dosage of use
Correct Incorrect Correct Incorrect
ACT 42 (33.0%) 85 (67.0%) 37 (29.4%) 90 (70.6%)
SP 120(82.0%) 27 (18.0%) 125 (85.0%) 22 (15.0%)
Quinine 27 (96.4%) 1 (3.6%) * *
Chloroquine 10 (34.5%) 19 (65.5%) 15 (51.7%) 14 (48.3%)
Amodiaquine *** *
ACT-Artemether combined therapy, SP-Sulphadoxine-pyrimethamine. Asterisks
(*) represent no response or “I don’t know”. More users of quinine and SP
could identify the correct duration of use.
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more days (60 hours or more), while 0.5% could not
remember.
Finally, when asked about what the respondents would
do if they missed their morning dose during treatment
course, 32.7% said they would ignore their missed dose,
25.9% indicated they would take it immediately they
remember, 21.2% said they would double the next dose,
15.6% said they would extend day of therapy, 2.8% said
they would narrow the dosing interval, while 1.8% gave
other actions.
Association between knowledge factors and anti-malarial
drug use patterns
In order to determine knowledge factors associated with
patterns of use of anti-malarial drugs in this peri-urban
population, a logistic regression analysis was performed.
The independent variables included knowledge on
symptoms for use, knowledge on dosage, knowledge on
duration, and knowledge on available anti-malarials. The
above factors were regressed against the outcome vari-
ables (i.e. drugs taken, duration of use and dosage/fre-
quency of use) (Table 2).
Knowledge on symptoms of malaria was a significant
factor in determining the type of anti-malarial drug
taken since many respondents took ACT (94.5%) and SP
(93.2%) against the presence or mixed symptoms of
headache, high temperature, shivering and vomiting as
compared to other symptoms mentioned (b = 0.063, P =
0.001) (Table 2).
Furthermore, knowledge on the anti-malarial drugs
available in the market significantly influenced the drug
taken (b = 0.013, P = 0.020) and dosages used (b =
0.121, P = 0.027) (Table 2), primarily due to the fact
that significantly higher proportions of respondents with
knowledge on availability of SP (78.5%) took SP against
symptoms of malaria and further took correct dosages
as opposed to individuals with knowledge on other
drugs (P = 0.002). Further analysis revealed that
knowledge on duration of use significantly influenced
the duration for which drugs were taken (b = 0.018, P =
0.022) since many individuals who used ACT took it for
shorter (incorrect) duration as compared to the indivi-
duals who used other anti-malarials (Table 2).
Discussion
This study has shown that populations living in malar-
ial-prone areas are generally knowledgeable about the
signs and symptoms of malaria such as high tempera-
tures, headache and vomiting. These findings are consis-
tent with other studies carried out in malaria endemic
areas in which knowledge on symptoms of malaria was
demonstrated [13,19,20]. For example, a study investi-
gating the prevalence of malaria among clients seeking
treatment for fever and/or malaria at drug store in rural
Tanzania [20] demonstrated that 24.0% of the people
who experienced fever and reported to drug stores to
purchase anti-malarial drugs were actually diagnosed
with malaria, even though 10.7% of them had reported
before that they had malaria/fever [20].
The households which accessed anti-malarials with
or without prescription in the current study were
equally knowledgeable about the symptoms of malaria
and would seek health care within 24 hours of onset of
symptoms. While health seeking behaviour within the
first 24 hours after the onset of symptoms is highly
commendable for this community, the actions reported
a f t e rm i s s i n gad o s ed u r i n gt h et r e a t m e n tc o u r s el i k e
ignoring a missed dose, doubling the next dose and
narrowing a dosing interval are worrying and poten-
tially requires an urgent public health intervention,
which should include educating the local populations
on the importance of taking drugs as prescribed.
Furthermore, such informal use of anti-malarial could
increase the risk of incorrect dosing, inappropriate
treatment and interactions of different medicines,
which could have a negative impact on malaria treat-
ment safety and efficacy.
Table 2 Knowledge factors and the use of anti-malarial drugs in Manyatta-B
Dependent variables
Drugs taken Dosage used Duration used
Constants 2.021 1.231 1.778
Knowledge variables
Symptoms for use b = 0.063, P = 0.001 b = 0.016, P = 0.849 b = 0.079, P = 0.150
Anti-malarial(s) availability b = 0.013, P = 0.020 b = 0.121, P = 0.027 b = 0.018, P = 0.722
Dosage b = 0.101, P = 0.341 b = 0.115, P = 0.279 b = 0.105, P = 0.322
Duration b = 0.192, P = 0.089 b = 0.039, P = 0.706 b = 0.018, P = 0.022
Logistic regression analysis between the independent and dependant variables was used to identify variables associated with the use of anti-malarial drugs, P-
values in bold were statistically significant at P ≤ 0.05. b = standard co-efficient. The result above shows that knowledge on symptoms for use and knowledge on
anti-malaria available work together to influence types of anti-malarial that are taken in the households. Furthermore, knowledge on the duration of use
determined the duration of which drugs were taken, while, knowledge on available anti-malarials determined the dosage used.
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behaviour may influence the patterns of anti-malarial
drug use. For instance, obtaining the anti-malarial drugs
without prescription is more of a common practice than
seeking prescription. This is not surprising given that
other studies had consistently demonstrated that self-
medication is common in most malaria-prone regions
[13]. Consistent with our observations, other studies car-
ried out in malaria endemic region of Uganda in which
focus was on malaria and medicine use in nine primary
schools, showed that in most cases, self-medication at
home was the first response to malaria both in rural
and urban areas in both teachers and students [21]. In
the current and in previous studies [13,21], the main
reasons for not seeking prescription included: the proce-
dure is less costly, the respondents’ similar experience
with the same illness/drugs and being not satisfied with
the services at the health facilities. It would be impor-
tant for health officers to emphasize on seeking pre-
scription and improve on the services at the health
facilities in such malaria endemic regions.
Assessment of patterns of drug use revealed intriguing
results. Although ACT and Quinine are the recom-
mended anti-malarials in Kenya at the moment, the cur-
rent data revealed that individuals with symptoms of
malaria have easy access to medications which are non-
efficacious to malaria, a phenomenon that had earlier
been documented in other regions of the country
[22,23]. For example, a study on the management of
fevers in Kenyan children and adults in a region of sea-
sonal transmission in Kenya found that majority (77.0%)
of visitors to shops received a medicine with no anti-
malarial efficacy at the time [23]. Surveys of treatment-
seeking behaviours in three districts in Kenya of ende-
mic malaria documented a similar access to drugs with
minimal malarial efficacy being distributed by local
shops for the treatment of individuals with symptoms of
malaria [22]. As such, accessing anti-malarials which
have lost efficacy in such malaria prone areas consisting
of population of semi-immune adults raises a health
concern, since the non-curative regimens may offer
symptomatic relief without parasitological cure, a situa-
tion which would increase the malaria burden in the
populations. Even when the recommended anti-malarial
drugs are used, inappropriate treatment regimens,
usually under-treatment, are common. In addition to
non-compliance with correctly-prescribed regimens,
much incorrect usage can be attributed to the practice
of purchasing medications directly from informal
sources without the benefit of any medical or prescrib-
ing advice, a practice that have been documented by
other studies in Kenya [5,24]. The findings that under-
treatment is frequent with doses of artemether/lumefan-
trine highlight the potential contribution of incorrect
drug usage to the genesis of drug resistant malaria in
these settings. As such, the government through their
policies should initiate training of personnel at the
sources (including those issuing drugs over the coun-
ters) on the importance of making available to the users,
only the most effective antimalarial drugs with proper
prescription. It is anticipated that this information will
further trickle down to the end user and lead to correct
usage of the anti-malarials.
Conclusion
Even though combination therapy looks promising to
fight drug resistant malaria, knowledge on the impor-
tance of adherence as well as availability of other less
effective anti-malarials in the market may be obstacles
to effective utilization of the therapy. This may adversely
affect up-scaling of the WHO new treatment policy on
malaria. It will be important for interventions to be
directed at creating awareness about changes in recom-
mended drugs so as to lessen the use of less efficacious
anti-malarials. In addition, the consumers need to be
educated on the importance of drug adherence in such
areas to reduce the emergence and spread of drug-resis-
tant malaria.
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